The envelope protein of tick-borne encephalitis virus influences neuron entry, pathogenicity, and vaccine protection.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Lindqvist, RichardRosendal, Ebba
Weber, Elvira
Asghar, Naveed
Schreier, Sarah
Lenman, Annasara
Johansson, Magnus
Dobler, Gerhard
Bestehorn, Malena
Kröger, Andrea
Överby, Anna K
Issue Date
2020-09-28
Metadata
Show full item recordAbstract
Background: Tick-borne encephalitis virus (TBEV) is considered to be the medically most important arthropod-borne virus in Europe. The symptoms of an infection range from subclinical to mild flu-like disease to lethal encephalitis. The exact determinants of disease severity are not known; however, the virulence of the strain as well as the immune status of the host are thought to be important factors for the outcome of the infection. Here we investigated virulence determinants in TBEV infection. Method: Mice were infected with different TBEV strains, and high virulent and low virulent TBEV strains were chosen. Sequence alignment identified differences that were cloned to generate chimera virus. The infection rate of the parental and chimeric virus were evaluated in primary mouse neurons, astrocytes, mouse embryonic fibroblasts, and in vivo. Neutralizing capacity of serum from individuals vaccinated with the FSME-IMMUN® and Encepur® or combined were evaluated. Results: We identified a highly pathogenic and neurovirulent TBEV strain, 93/783. Using sequence analysis, we identified the envelope (E) protein of 93/783 as a potential virulence determinant and cloned it into the less pathogenic TBEV strain Torö. We found that the chimeric virus specifically infected primary neurons more efficiently compared to wild-type (WT) Torö and this correlated with enhanced pathogenicity and higher levels of viral RNA in vivo. The E protein is also the major target of neutralizing antibodies; thus, genetic variation in the E protein could influence the efficiency of the two available vaccines, FSME-IMMUN® and Encepur®. As TBEV vaccine breakthroughs have occurred in Europe, we chose to compare neutralizing capacity from individuals vaccinated with the two different vaccines or a combination of them. Our data suggest that the different vaccines do not perform equally well against the two Swedish strains. Conclusions: Our findings show that two amino acid substitutions of the E protein found in 93/783, A83T, and A463S enhanced Torö infection of neurons as well as pathogenesis and viral replication in vivo; furthermore, we found that genetic divergence from the vaccine strain resulted in lower neutralizing antibody titers in vaccinated individuals.Citation
J Neuroinflammation. 2020 Sep 28;17(1):284. doi: 10.1186/s12974-020-01943-w.Affiliation
TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.Publisher
BMCJournal
Journal of neuroinflammationPubMed ID
32988388Type
ArticleLanguage
enEISSN
1742-2094ae974a485f413a2113503eed53cd6c53
10.1186/s12974-020-01943-w
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.
- Authors: Tsetsarkin KA, Maximova OA, Liu G, Kenney H, Teterina NL, Pletnev AG
- Issue date: 2019 Apr 23
- Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.
- Authors: Beck Y, Fritz R, Orlinger K, Kiermayr S, Ilk R, Portsmouth D, Pöllabauer EM, Löw-Baselli A, Hessel A, Kölch D, Howard MK, Barrett PN, Kreil TR
- Issue date: 2016 Feb 15
- Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
- Authors: Pletnev AG, Bray M, Hanley KA, Speicher J, Elkins R
- Issue date: 2001 Sep
- Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype.
- Authors: Heiss BL, Maximova OA, Pletnev AG
- Issue date: 2011 Feb
- Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
- Authors: Domnich A, Panatto D, Arbuzova EK, Signori A, Avio U, Gasparini R, Amicizia D
- Issue date: 2014